TELA Bio, Inc. (TELA) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
TELA currently has 44.8M outstanding shares. with minimal authorized share overhang for future dilution. The company has significantly diluted shareholders by 78.64% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 13, 2026 |
10-Q filing | 44.8M shares outstanding |
45M | 0 |
| Mar 25, 2026 |
10-K filing | 46.9M shares outstanding |
47M | 0 |
| Dec 12, 2025 |
S-3 filing: This S-3 filing from 2025-12-12 registers up to 2,000,000 shares of common stock for resale by a selling stockholder, issuable upon exercise of a warrant related to a credit agreement. |
40M | 0 |
| Nov 14, 2025 |
10-Q filing | 40.3M shares outstanding |
40M | 0 |
| Nov 14, 2025 |
8-K filing: TELA Bio, Inc. entered into a credit agreement for a $70.0 million term loan facility and a registered direct offering of common stock and pre-funded warrants, with expected net proceeds of approximately $11.9 million. ($13.01M proceeds) |
40M | 0 |
| May 08, 2025 |
10-Q filing | 39.6M shares outstanding |
40M | 0 |
| Mar 21, 2025 |
10-K filing | 39.6M shares outstanding |
40M | 0 |
| Nov 08, 2024 |
10-Q filing | 24.7M shares outstanding |
25M | 0 |
| Oct 23, 2024 |
8-K filing: TELA Bio, Inc. entered into an underwriting agreement relating to the issuance and sale of 12,000,000 shares of common stock at $2.25 per share and pre-funded warrants to purchase up to 5,800,000 shares of common stock at $2.2499 per warrant, with an option for the underwriters to purchase up to an additional 2,670,000 shares. ($27.0M proceeds) |
25M | 0 |
| Aug 13, 2024 |
10-Q filing | 24.7M shares outstanding |
25M | 0 |
| May 10, 2024 |
10-Q filing | 24.6M shares outstanding |
25M | 0 |
| Mar 22, 2024 |
10-K filing | 22.9M shares outstanding |
23M | 710K |
| Nov 13, 2023 |
S-3 filing: The company may offer and sell up to $150,000,000 in the aggregate of any combination of common stock, preferred stock, debt securities, warrants, units, and subscription rights from time to time in one or more offerings, and also offers common stock through an at-the-market offering. |
24M | 0 |
| Nov 13, 2023 |
10-Q filing | 24.5M shares outstanding |
24M | 0 |
| Aug 10, 2023 |
10-Q filing | 23.2M shares outstanding |
23M | 0 |
| May 11, 2023 |
10-Q filing | 19.2M shares outstanding |
19M | 0 |
| Apr 20, 2023 |
8-K filing: TELA Bio, Inc. entered into an underwriting agreement to issue and sell 4,750,000 shares of common stock at $9.50 per share in an offering expected to close on April 21, 2023. ($45.13M proceeds) |
19M | 0 |
| Mar 23, 2023 |
10-K filing | 19.2M shares outstanding |
19M | 0 |
| Nov 10, 2022 |
10-Q filing | 19.2M shares outstanding |
19M | 0 |
| Aug 17, 2022 |
8-K filing: TELA Bio, Inc. completed an offering of 4,000,000 shares of common stock at $8.00 per share, with an additional 600,000 shares sold through the underwriter's option, resulting in net proceeds of approximately $34.2 million for working capital and general corporate purposes. ($36.8M proceeds) |
15M | 300K |
| Aug 11, 2022 |
10-Q filing | 14.6M shares outstanding |
15M | 3.1M |
| May 11, 2022 |
10-Q filing | 14.5M shares outstanding |
15M | 3.2M |
| Mar 23, 2022 |
10-K filing | 14.5M shares outstanding |
14M | 3.2M |
| Nov 12, 2021 |
10-Q filing | 14.5M shares outstanding |
15M | 3.2M |
| Aug 12, 2021 |
10-Q filing | 14.5M shares outstanding |
14M | 3.2M |
| May 14, 2021 |
10-Q filing | 14.4M shares outstanding |
14M | 3.3M |
| Mar 25, 2021 |
10-K filing | 14.4M shares outstanding |
14M | 3.3M |
| Dec 18, 2020 |
S-3 filing: The company may offer and sell up to $150,000,000 in various securities, including common stock, preferred stock, debt securities, warrants, units, and subscription rights, from time to time. The company also is offering common stock via an at-the-market offering for up to $50,000,000 through Piper Sandler. |
14M | 3.3M |
| Nov 12, 2020 |
10-Q filing | 14.4M shares outstanding |
14M | 430K |
| Aug 13, 2020 |
10-Q filing | 14.4M shares outstanding |
14M | 440K |
| Jun 30, 2020 |
8-K filing: TELA Bio, Inc. closed its underwritten public offering of 3,000,000 shares of common stock at $16.00 per share, resulting in $48.0 million of gross proceeds. ($48.0M proceeds) |
11M | 3.5M |
| Jun 23, 2020 |
S-1 filing: TELA Bio, Inc. is offering 3,000,000 shares of its common stock in a public offering, with an option for the underwriters to purchase an additional 450,000 shares. |
11M | 3.5M |
| May 15, 2020 |
10-Q filing | 11.4M shares outstanding |
11M | 0 |
| Mar 30, 2020 |
10-K filing | 11.4M shares outstanding |
11M | 0 |